FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
About this item
Full title
Author / Creator
Publisher
United States: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI), is an effective treatment for non‐small‐cell lung cancer (NSCLC) with EGFR activating mutations, but inevitably, the clinical efficacy is impeded by the emergence of acquired resistance. The tumor suppressor gene FBXW7 modulates chemosensitivity in various human ca...
Alternative Titles
Full title
FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c5520567791d4b7b8da29f0bd15cb759
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c5520567791d4b7b8da29f0bd15cb759
Other Identifiers
ISSN
1574-7891
E-ISSN
1878-0261
DOI
10.1002/1878-0261.12200
